Humacyte's Bioengineered Vessel Shows Low Atherosclerosis Susceptibility in Long-Term Clinical Study
- Humacyte announced long-term clinical results showing low susceptibility to atherosclerosis in its acellular tissue-engineered vessel, with minimal lipid buildup and no vulnerable plaques.
- The analysis covered 52 patients across five clinical trials, including vessels implanted for more than five years.
- Findings were presented at the 2026 ISVTE-ISACB Joint Meeting in Miami, supporting the vessel’s potential long-term durability.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160800PRIMZONEFULLFEED9877963) on November 16, 2026, and is solely responsible for the information contained therein.